AI assistant
PTC THERAPEUTICS, INC. — Director's Dealing 2017
Jan 6, 2017
31046_dirs_2017-01-05_603aeb5b-d4d5-44f8-9526-e36372b78ced.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: PTC THERAPEUTICS, INC. (PTCT)
CIK: 0001070081
Period of Report: 2017-01-03
Reporting Person: Rothera Mark (Chief Commercial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-01-03 | Common Stock | A | 9600 | — | Acquired | 22523 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-01-03 | Stock Option (Right To Buy) | $11.23 | A | 56000 | Acquired | 2027-01-02 | Common Stock (56000.0) | Direct |
Footnotes
F1: Restricted stock awarded to the Reporting Person vests in four equal annual installments over four years, commencing on January 3, 2018.
F2: Includes 1,707 shares acquired under the Issuer's employee stock purchase plan for the period ending December 31, 2016.
F3: This option was granted on January 3, 2017, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2018, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2018.